Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma | Zendy

Robert J. Motzer | Zendy; B. Yа. Alekseev | Zendy; Sun Young Rha | Zendy; Camillo Porta | Zendy; Masatoshi Eto | Zendy; Thomas Powles | Zendy; Viktor Grünwald | Zendy; Thomas E. Hutson | Zendy; Evgeny Kopyltsov | Zendy; María José Méndez-Vidal | Zendy; Vadim Kozlov | Zendy; Anna Alyasova | Zendy; SungHoo Hong | Zendy; Anil Kapoor | Zendy; Teresa Alonso Gordoa | Zendy; Jaime R. Merchan | Zendy; Eric Winquist | Zendy; Pablo Maroto | Zendy; Jeffrey C. Goh | Zendy; Miso Kim | Zendy; Howard Gurney | Zendy; Vijay Patel | Zendy; Avivit Peer | Zendy; Giuseppe Procopio | Zendy; Toshio Takagi | Zendy; Bohuslav Melichar | Zendy; Frédéric Rolland | Zendy; Ugo De Giorgi | Zendy; Shirley Wong | Zendy; Jens Bedke | Zendy; Manuela Schmidinger | Zendy; Corina E. Dutcus | Zendy; Alan D. Smith | Zendy; Lea Dutta | Zendy; Kalgi Mody | Zendy; Rodolfo F. Perini | Zendy; Dongyuan Xing | Zendy; Toni K. Choueiri | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Author(s) -

Robert J. Motzer,

B. Yа. Alekseev,

Sun Young Rha,

Camillo Porta,

Masatoshi Eto,

Thomas Powles,

Viktor Grünwald,

Thomas E. Hutson,

Evgeny Kopyltsov,

María José Méndez-Vidal,

Vadim Kozlov,

Anna Alyasova,

SungHoo Hong,

Anil Kapoor,

Teresa Alonso Gordoa,

Jaime R. Merchan,

Eric Winquist,

Pablo Maroto,

Jeffrey C. Goh,

Miso Kim,

Howard Gurney,

Vijay Patel,

Avivit Peer,

Giuseppe Procopio,

Toshio Takagi,

Bohuslav Melichar,

Frédéric Rolland,

Ugo De Giorgi,

Shirley Wong,

Jens Bedke,

Manuela Schmidinger,

Corina E. Dutcus,

Alan D. Smith,

Lea Dutta,

Kalgi Mody,

Rodolfo F. Perini,

Dongyuan Xing,

Toni K. Choueiri

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2035716

Subject(s) - lenvatinib , pembrolizumab , everolimus , sunitinib , renal cell carcinoma , medicine , oncology , immunotherapy , cancer , thyroid cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore